Abstract
Cisplatin-based combinations are efficacious in increasing the overall survival of patients with non-small cell lung cancer (NSCLC), but their toxicity makes them unsuitable for elderly and unfit patients. The primary objective of this non-randomized phase II study was to evaluate the feasibility and activity of the gemcitabine plus vinorelbine combination in previously untreated elderly and/or unfit patients with measurable stage III or IV NSCLC. Forty-three patients aged ≥ 65 years or with contraindications against cisplatin treatment (36 males and seven females: median age 66 years; range 48–75: PS 0 = 11, PS 1 = 19, PS 2 = 13) received intravenous (i.v.) gemcitabine 1000 mg m–2, followed by vinorelbine 25 mg m–2 i.v. on day 1 and 8 every 21 days. Fifteen patients (34.9%) achieved partial remission (confidence interval: 27.6–42.2%) for a median duration of 6 months; the median survival of these patients has not yet been reached. A further 15 had stable disease for a median of 4 months and a median survival of 7 months. The 10 patients (23.2%) who experienced disease progression had a median survival of 4 months. Three patients are not evaluable. The 1-year actuarial survival rate is 31.1%. The treatment was well tolerated: only 35% of the patients had grade 3 or 4 granulocytopenia on day 14, none experienced episodes of neutropenic fever, and there was no evidence of severe haematological toxicity upon recycling. Only 9% of the patients suffered from gastrointestinal toxicity (grade 3); increased but reversible transaminase levels were observed in 11.6%. In conclusion, the results of this phase II study show that the combination of gemcitabine and vinorelbine is active and well tolerated in NSCLC, and thus encourage its use in elderly or unfit patients. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bonomi P (1999) Review of paclitaxel/carboplatin in advanced non-small cell lung cancer. Semin Oncol 26(suppl 2): 55–59
Bunn PA Jr (1993) Future directions in the management of non-small cell lung cancer. Lung Cancer 9(suppl 2): 91–127
Cigolari S, Gridelli C, Frontini L, Gulisano M, Robbiati SF, Farris A, Clerici M, Castiglione F, Piazza E, Ianniello GP & Perrone F (1998) Gemcitabine + vinorelbine (GEMVIN) in the treatment of advanced non-small cell lung cancer (NSCLC). Sequential phase I and phase II trials. Proc ESMO 9: 87
De Candis D, Bidoli P, Cresta S, Artale S, Masi G & Bajetta E (1998) Phase II study of gemcitabine (GEM) plus navelbine (NVB) in previously untreated stage III or IV non-small cell lung cancer (NSCLC). Proc ESMO 9: 95
Esteban E, Llano JLG, Vieitez Jm, Fra J, Puertas J, Estrada E, Palacio I, Mumiz I, Buesa JM & Lacave AJ (1998) Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 482a
Feliu J, Lopez-Gomez L, Madronal C, Jalon I, Garcia-Giron J, Castro J, Martinez B, Iglesias J, Zamora P & Gonzales-Baron M (1998) Phase II study of gemcitabine-vinorelbine (G-V) in patients with advanced non-small cell lung cancer (NSCLC) over 70 year-old or with contraindication to receive cisplatin. Proc ESMO 9: 85
Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S & Glisson B (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractary non-small cell lung cancer. J Clin Oncol 13: 645–651
Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Pacilio C, Gravina A, Caputi V, Botti G & Comella G (1997) Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a Phase I study. Ann Oncol 8: 1045–1048
Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S & Masuda N (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16–20
Gatzemeier U, Heckmayr M, Neuhauss R, Schluter I, Pawel JV, Wagner H & Dreps A (1995) Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 12(suppl 2): 101–106
Goss GD, Logan DM, Newmann TE & Evans WK (1997) Use of vinorelbine in non-small cell lung cancer. Provincial Lung Disease Site Group. Cancer Prev Control 1: 28–38
Isokangas OP, Knuuttila A, Halme M, Mantyla M, Lindstrom I, Nakkanen V, Viren M, Joensuu H & Mattson K (1999) Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol 10: 1059–1063
Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G & Thiriaux J (1990) A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8: 1556–1562
Langer CJ, Leigthon JC, Comis RL, O’Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S & Ozols RF (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860–1870
Le Chevalier T (1996) Chemotherapy of non-small-lung cancers. Presse Med 25: 1699–1703
Lilenbaum RC & Green MR (1993) Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 11: 1391–1402
Lilenbaum RC, Schwartz MA, Cano R, Krill E, Lutzky J, Baulstein A, Seigel L, Viales M, Dominguez CJ & Davila E (1998) Gemcitabine (GEM) and navelbine (NVB) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 494a
Lorusso V, Carpagnano F, Frasci G, Panza N, Di Rienzo G, Cisternino ML, Napoli G, Orlando S, Cinieri S, Brunetti C, Palazzo S & De Lena M (2000) Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J Clin Oncol 18: 405–411
Noble S & Goa KL (1997) Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54: 447–472
Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899–909
Non Small Cell Lung Cancer Expert Panel (1997) Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 15: 2996–3018
Parker SL, Tong T, Bolden S & Wingo PA (1996) Cancer statistics. CA Cancer J Clin 65: 5–27
Simon R (1989) Optimal two-stage design for phase II clinical trials. Control Clin Trials 10: 1–10
Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E & Rapp E (1993) Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342: 19–21
The Elderly Lung Cancer Vinorelbine Italian Study Group (E. L. C. V. I. S) (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66–72
Zanetti R, Buiatti E, Federico M & Micheli A (1998) Fatti e cifre dei tumori in Italia. II Pensiero Scientifico: Roma
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Beretta, G., Michetti, G., Belometti, M. et al. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 83, 573–576 (2000). https://doi.org/10.1054/bjoc.2000.1304
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1304
Keywords
This article is cited by
-
Selection of Patients in Ongoing Clinical Trials on Lung Cancer
Lung (2016)
-
Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: a meta-analysis
The Chinese-German Journal of Clinical Oncology (2011)
-
The pooled analysis of single gemcitabine for non-small cell lung cancer patients with elderly age
The Chinese-German Journal of Clinical Oncology (2010)
-
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter
Cancer Chemotherapy and Pharmacology (2007)
-
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)
British Journal of Cancer (2003)